Pharmaceutical industry in China

TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021

Retrieved on: 
Wednesday, August 4, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.

Key Points: 
  • Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.
  • The Company will host a conference call on Thursday, August 12, 2021, at 4:30 PM EDT to review the clinical, corporate and financial highlights.
  • Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
  • TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Pharmacy

DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.

Key Points: 
  • DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 2454465.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Pharmaceuticals policy, Health care, Health, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Trademark, European Medicines Agency, NASDAQ, Mesoblast

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.
  • Expects to announce top-line results from the INTRIGUE Phase 3 study in the fourth quarter of 2021.
  • Expects potential approval from the European Medicines Agency (EMA) for QINLOCK in the fourth quarter of 2021.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Life sciences, Class III PI 3-kinase, Autophagy, Pharmaceutical industry in China

STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.

Key Points: 
  • STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.
  • The chosen partner, Deciphera Pharmaceuticals Inc., founded in 2003, is a pharmaceutical company focused on delivering important new medicines to patients for the treatment of cancer.
  • With a clear focus on improving the lives of people living with cancer and demonstrated expertise in bringing a new drug to market, Deciphera is considered to be an extremely attractive partner for the Sprint Biosciences Vps34 program.
  • This Vps34 program fits well with our growing pipeline, and enhances our efforts to explore the potential for regulating autophagy in cancer," said Dan Flynn, Executive Vice President and Chief Scientific Officer (CSO) of Deciphera Pharmaceuticals.

Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Life sciences, Class III PI 3-kinase, Autophagy, Pharmaceutical industry in China

STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.

Key Points: 
  • STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals.
  • The chosen partner, Deciphera Pharmaceuticals Inc., founded in 2003, is a pharmaceutical company focused on delivering important new medicines to patients for the treatment of cancer.
  • With a clear focus on improving the lives of people living with cancer and demonstrated expertise in bringing a new drug to market, Deciphera is considered to be an extremely attractive partner for the Sprint Biosciences Vps34 program.
  • This Vps34 program fits well with our growing pipeline, and enhances our efforts to explore the potential for regulating autophagy in cancer," said Dan Flynn, Executive Vice President and Chief Scientific Officer (CSO) of Deciphera Pharmaceuticals.

Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry

The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.

Key Points: 
  • The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
  • And it's not just an "old-person" problem; nearly one in four adults aged 20 to 44 have high blood pressure.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space.
  • Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers.

Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (CDC), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don't even know they have it. The urgency of finding effective treatments for this life-threatening disease can't be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
  • And it's not just an "old-person" problem; nearly one in four adults aged 20 to 44 have high blood pressure.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space.
  • Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 2, 2021
Health, Burlingame, California, Investigational New Drug, Pharmaceutical industry in China

BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
  • The endpoint of the clinical trial is response rate and results are anticipated by year end 2021.
  • Angel Pharmaceuticals has filed an investigational new drug application (IND) for CPI-818 with the Center for Drug Evaluation (CDE) in China.
  • Angel Pharmaceuticals was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

Retrieved on: 
Monday, August 2, 2021
Bristol Myers Squibb, Life sciences, Madrigal, Pharmaceutical industry in China, Health care, Health sciences

CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert

Key Points: 
  • CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert
    Waltermire has joined Madrigal as Chief Pharmaceutical Development Officer.
  • We are pleased to announce that Dr. Robert Waltermire has joined the Madrigal R&D team.
  • Paul Friedman, CEO of Madrigal added, "We look forward to reconnecting with Rob at Madrigal after having worked with him at Dupont earlier in his career.
  • From 1988 to 2020, Dr. Waltermire held positions of increasing responsibility at Bristol-Myers Squibb (and Dupont Pharmaceutical Company) including Vice President Chemical & Synthetic Development at BMS.

Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management

Retrieved on: 
Monday, August 2, 2021
Life sciences, Companies, Industry economics), Bristol Myers Squibb, Novartis, Pharmaceutical industry in China, Project management

Dr. Randall White brings over 20 years of pharmaceutical research and development experience to the Windtree team.

Key Points: 
  • Dr. Randall White brings over 20 years of pharmaceutical research and development experience to the Windtree team.
  • Prior to that, Dr. White was the Head of Project Management for the Early Immuno-Oncology portfolio at Bristol-Myers Squibb, where he drove strategy and project management oversight.
  • His earlier roles included Senior Project Manager at Sandoz Pharmaceuticals and Project Manager of Clinical Development at Protarga.
  • We are thrilled to welcome Randy to the Windtree team," saidSteve Simonson, M.D., Senior Vice President and Chief Medical Officer of Windtree.